scholarly journals GPR43 suppresses intestinal tumor growth by modification of the mammalian target of rapamycin complex 1 activity in ApcMin/+ mice

2021 ◽  
Author(s):  
Lingling Kong ◽  
Namiko Hoshi ◽  
Yunlong Sui ◽  
Yasutaka Yamada ◽  
Ryutaro Yoshida ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Intestinal Tumor

scholarly journals CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma

2016 ◽  
Vol Volume 9 ◽  
pp. 5985-5997 ◽  
Author(s):  
Xu Li ◽  
Leiming Li ◽  
Yan Li ◽  
Jiansong Zhao ◽  
Shuli Fan ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Signaling Pathways ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin

Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary

2014 ◽  
Vol 24 (3) ◽  
pp. 444-453 ◽  
Author(s):  
Akiko Kudoh ◽  
Tetsuro Oishi ◽  
Hiroaki Itamochi ◽  
Seiya Sato ◽  
Jun Naniwa ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Tumor Growth ◽  
Cell Lines ◽  
Mucinous Adenocarcinoma ◽  
Inhibitory Concentration ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Phosphatidylinositol 3 Kinase ◽  
Xenograft Models ◽  
Phosphatidylinositol 3

AbstractOvarian mucinous adenocarcinoma (MAC) resists standard chemotherapy and is associated with poor prognosis. A more effective treatment is needed urgently. The present study assessed the possibility of molecular-targeted therapy with a novel dual inhibitor of phosphatidylinositol 3′-kinase (PI3K) and mammalian target of rapamycin (mTOR), NVP-BEZ235 (BEZ235) to treat of MAC. Seven human MAC cell lines were used in this study. The sensitivity of the cells to BEZ235, temsirolimus, and anticancer agents was determined with the WST-8 assay. Cell cycle distribution was assessed by flow cytometry, and the expression of proteins in apoptotic pathways and molecules of the PI3K/Akt/mTOR signaling pathways was determined by Western blot analysis. We also examined the effects of BEZ235 on tumor growth in nude mice xenograft models. The cell lines showed half-maximal inhibitory concentration values of BEZ235 from 13 to 328 nmol/L. Low half-maximal inhibitory concentration values to BEZ235 were observed in MCAS and OMC-1 cells; these 2 lines have an activating mutation in the PIK3CA gene. NVP-BEZ235 down-regulated the protein expression of phosphorylated (p-) Akt, p-p70S6K, and p-4E-BP1, suppressed cell cycle progression, up-regulated the expression of cleaved PARP and cleaved caspase 9, and increased apoptotic cells. Synergistic effects were observed on more than 5 cell lines when BEZ235 was combined with paclitaxel or cisplatin. The treatment of mice bearing OMC-1 or RMUG-S with BEZ235 significantly suppressed tumor growth in MAC xenograft models without severe weight loss. We conclude that the PI3K/Akt/mTOR pathway is a potential therapeutic target and that BEZ235 should be explored as a therapeutic agent for MAC.

scholarly journals Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway

2019 ◽  
Vol 79 (3) ◽  
pp. 685-685 ◽  
Author(s):  
Xiufeng Pang ◽  
Zhengfang Yi ◽  
Jing Zhang ◽  
Binbin Lu ◽  
Bokyung Sung ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin

scholarly journals Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth

2012 ◽  
Vol 33 (11) ◽  
pp. 2283-2292 ◽  
Author(s):  
Charlène Rico ◽  
Marie-Noëlle Laguë ◽  
Pavine Lefèvre ◽  
Mayra Tsoi ◽  
Aurore Dodelet-Devillers ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Granulosa Cell ◽  
Mammalian Target Of Rapamycin ◽  
Granulosa Cell Tumor ◽  
Cell Tumor ◽  
Target Of Rapamycin ◽  
Ovarian Granulosa Cell ◽  
Ovarian Granulosa Cell Tumor
Sign in / Sign up

Export Citation Format

Share Document